Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

214
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
214
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

15
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
15
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

238
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.

European radiology experimental·2026
Same author

A stimuli-responsive <i>ex vivo</i> model of osteoarthritis demonstrates TLR4-mediated cartilage degradation and a Rapamycin-induced fast matrix recovery.

bioRxiv : the preprint server for biology·2026
Same author

Ultrasound assessment of diaphragmatic structure and function before and after orthotopic liver transplantation in MNGIE.

Journal of ultrasound·2026
Same author

AI Revolution in Radiology, Radiation Oncology and Nuclear Medicine: Transforming and Innovating the Radiological Sciences.

Journal of medical imaging and radiation oncology·2025
Same author

Cerebral circuits involved in preferential hand posture representation for action.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2025
Same author

Biofabrication of an<i>in situ</i>hypoxia-delivery scaffold for cartilage regeneration.

Biofabrication·2025
Same journal

Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers.

Technology in cancer research & treatment·2026
Same journal

Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.

Technology in cancer research & treatment·2026
Same journal

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Technology in cancer research & treatment·2026
Same journal

EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies.

Technology in cancer research & treatment·2026
Same journal

Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.

Technology in cancer research & treatment·2026
Same journal

A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy.

Technology in cancer research & treatment·2026
See all related articles

Related Experiment Video

Updated: Aug 9, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.1K

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH).

L V Sciacqua1, A Vanzulli1, R Di Meo1

  • 1Residency Program in Diagnostic and Interventional Radiology, Università degli Studi di Milano, Milan, Italy.

Technology in Cancer Research & Treatment
|February 16, 2023
PubMed
Summary
This summary is machine-generated.

Minimally-invasive treatments for benign prostatic hyperplasia (BPH) are effective and safe alternatives to surgery for relieving lower urinary tract symptoms (LUTS). These advanced procedures offer comparable results with a lower incidence of adverse effects.

Keywords:
benign prostatic hyperplasiainterventional radiologylow urinary tract symptomminimal invasive treatmentsprostate

More Related Videos

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.3K

Related Experiment Videos

Last Updated: Aug 9, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.1K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.3K

Area of Science:

  • Urology
  • Minimally Invasive Procedures
  • Medical Technology

Background:

  • Benign Prostatic Hyperplasia (BPH) is a common condition causing Lower Urinary Tract Symptoms (LUTS).
  • Traditional surgical interventions, while effective, carry significant risks and side effects.
  • There is a growing need for safer, less invasive treatment options for BPH patients.

Approach:

  • A comprehensive systematic review of peer-reviewed literature published between 1993 and 2022.
  • Inclusion of original research articles, reviews, and case studies from public repositories.
  • Focus on evaluating the efficacy and safety profiles of various minimally invasive BPH treatments.

Key Points:

  • Prostate Artery Embolization (PAE), Transurethral Needle Ablation (TUNA), Transurethral Microwave Thermotherapy (TUMT), High Intensity Focused Ultrasound (HIFU), laser treatments, and Cryoablation were assessed.
  • These minimally invasive techniques demonstrate validity and safety in managing LUTS associated with BPH.
  • Reported undesired effects are generally fewer compared to traditional surgical methods.

Conclusions:

  • Minimally invasive treatments represent viable and safe alternatives to surgery for BPH-related LUTS.
  • Patients may experience comparable symptom relief with an improved safety profile.
  • Further research and clinical adoption of these techniques are warranted.